

MITRE / FLUX NOTES **TREATMENT OPTIONS v7**

EDWIN CHOI, DANIEL REEVES, JUHAN SONIN, 9.JAN.2018



0 Clickable prototype



Full version:

https://www.figma.com/proto/H95uNzkCJvMu0ZbKPafOsAF7/treatment_options?node-id=22%3A14148&viewport=305%2C-1651%2C0.5&scaling=min-zoom

MVP:

https://www.figma.com/proto/H95uNzkCJvMu0ZbKPafOsAF7/treatment_options?node-id=22%3A10126&viewport=961%2C643%2C0.5&scaling=min-zoom

I COLLABORATIVE VIEW

Future version

Multiple viz styles

Display descriptions and additional resources

Compare these treatments [select treatments](#)


surgery alone	1-2 line description w/ reference to external resource
+ homonal therapy	1-2 line description w/ reference to external resource
+ chemotherapy	1-2 line description w/ reference to external resource
+ hormonal therapy & chemotherapy	1-2 line description w/ reference to external resource

Using these outcomes [select outcomes](#)

overall survival rate	description of overall survival rate
reported severe side effects	description of this other metric



table



text



icons



chart

1 yr



2 yr

5 yr

With **surgery alone**, **68%** of patients will survive 1 year, with 30% dying due to cancer. **10%** are hospitalized due to side effects, most commonly due to **pain**.

With **chemotherapy** in addition to surgery, **5% additional** patients will survive 1 year. **2% more** are hospitalized due to side effects, most commonly due to **neuropathy**.

With **chemotherapy & radiation** in addition to surgery, **12% additional** patients will survive 1 year. **4% more** are hospitalized due to side effects, most commonly due to **blood clots**.



Date of birth
5 Apr 1966 (51)

Admin. sex
Female

Location
Boston, MA

ROID
12345432312

Language
Spanish

Condition

Ductal carcinoma of the breast ▼



Compare these treatments [select treatments](#)

surgery alone

+ hormonal therapy

+ chemotherapy

+ hormonal therapy & chemotherapy

1-2 line description w/ reference to external resource

1-2 line description w/ reference to external resource

1-2 line description w/ reference to external resource

1-2 line description w/ reference to external resource

Using these outcomes [select outcomes](#)

overall survival rate

reported severe side effects

description of overall survival rate

description of this other metric




1 yr

2 yr

5 yr

55/100 survive with surgery only




+5 survive with chemotherapy

+3 survive with radiation

+7 survive with radiation
and chemotherapy

40/100 die from cancer
with surgery only

5/100 die from causes



Compare these treatments [select treatments](#)

surgery alone	1-2 line description w/ reference to external resource
+ homonal therapy	1-2 line description w/ reference to external resource
+ chemotherapy	1-2 line description w/ reference to external resource
+ hormonal therapy & chemotherapy	1-2 line description w/ reference to external resource

Using these outcomes [select outcomes](#)

overall survival rate	description of overall survival rate
reported severe side effects	description of this other metric

table


text

icons

chart

1 yr 2 yr 5 yr

Patient survival over time



2 PRINTING

priority to support printing



Language
Spanish

Condition
Ductal carcinoma of the breast

Using the following data, we create a cohort of **1,245** patients like you.

Then, we compare outcomes across the different treatments they received.

condition: invasive ductal carcinoma of the breast

demographic

age at diagnosis	50-60
sex	male
race	white

genetics

BRCA1	negative
BRCA2	negative

pathology

grade	3
stage	IIIA
size	10-20 mm
ER	negative
PR	positive
HER2	positive

Compare these treatments

surgery alone	1-2 line description w/ reference to external resource
+ homonal therapy	1-2 line description w/ reference to external resource
+ chemotherapy	1-2 line description w/ reference to external resource
+ hormonal therapy & chemotherapy	1-2 line description w/ reference to external resource

Using these outcomes

overall survival rate	description of overall survival rate
hospitalization due to side effects	description of this other metric

Additional Resources:

- curated resources that may be condition specific
- curated resources that may be condition specific
- curated resources that may be condition specific

print these visualizations:





text



cons



chart

1 yr

2 yr

5 yr


Of every 100 patients...

overall survival:



67 survive after 1 yr

number reporting severe effects:




combined with:

hormonal therapy & chemotherapy (64)	+ 12 more survive	dyspnoea	anemia	blood clots	pain
hormonal therapy (76)	+ 6 more survive	dyspnoea	pain		
chemotherapy (12)	+ 8 more survive	pain	anemia	blood clots	peripheral motor neuro.

With **surgery alone**, **68%** of patients will survive 1 year, with 30% dying due to cancer. **10%** are hospitalized due to side effects, most commonly due to **pain**.

With **chemotherapy** in addition to surgery, **5% additional** patients will survive 1 year. **2% more** are hospitalized due to side effects, most commonly due to **neuropathy**.

With **chemotherapy & radiation** in addition to surgery, **12% additional** patients will survive 1 year. **4% more** are hospitalized due to side effects, most commonly due to **blood clots**.




3 MVP

Primarily Clinician use

Push to include icon based graphic

Support for side effect data uncertain

Potential to include non-personalized side-effect information



Treatment Options

Ductal carcinoma of the breast

Outcomes and criteria for 156,765 patients with Ductal carcinoma of the breast were collected by CancerLinQ [...more](#)

Similar patients 156 patients

criteria: *age, age at diagnosis, sex, genetics, pathology*

[select all](#) [select none](#)

- demographic 3/4

☒ age: 41-61

☒ age at diagnosis: 41-61

☐ race: white

☒ sex: female
- genetics 2/2

☒ BRCA1: negative

☒ BRACA2: negative
- pathology 5/5


☒ ER: negative

☒ PR: positive

☒ HER2: positive

☒ grade: 3

☒ size (mm): 10-20



4 Other explorations

Compare these treatments

select treatments

surgery alone	1-2 line description w/ reference to external resource
+ homonal therapy	1-2 line description w/ reference to external resource
+ chemotherapy	1-2 line description w/ reference to external resource
+ hormonal therapy & chemotherapy	1-2 line description w/ reference to external resource

Using these outcomes

select outcomes

overall survival rate	description of overall survival rate
reported severe side effects	description of this other metric

table

text

icons

chart

1 yr

2 yr

5 yr

